Insmed vs Viatris

Insmed (INSM), health care, and Viatris (VTRS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Insmed is worth $26.7B on the stock market and Viatris $23.4B: Insmed is valued at 14% more. Insmed's operating margin in its latest fiscal year was -206% and Viatris's -18.6%. Over the past year Insmed's share price has moved -39.1% and Viatris's +93.7%.

Key facts

Insmed market value
$26.7B
Viatris market value
$23.4B
Insmed revenue
$606.4MFY to 2025-12-31
Viatris revenue
$14.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Insmed vs Viatris: every measure side by side
Measure Insmed Viatris
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$26.7Bhigher$23.4Blower
Revenue$606.4Mlower$14.3Bhigher
Earnings-$1.3Bhigher-$3.5Blower
Employees1,664lower30,000higher
Total assets$2.3Blower$37.2Bhigher
Valuation
P/E——
P/S44.1higher1.6lower
P/B36.8higher1.7lower
Dividend yield0.00%lower2.31%higher
Profitability
Operating margin-206%lower-18.6%higher
Balance sheet
Net assets$739Mlower$14.7Bhigher
Total liabilities$1.5Blower$22.5Bhigher
Total debt$546.8Mlower$14.4Bhigher
Cash on hand$510.4Mlower$1.3Bhigher
Price change
Today-0.83%higher-1.40%lower
1 year-39.1%lower+93.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns INSM · Who owns VTRS

Further comparisons

Learn

Questions and answers

Which is bigger, Insmed or Viatris?

By market value, Insmed is the larger: $26.7B against $23.4B for Viatris. By revenue in its latest fiscal year, Viatris is the larger: $14.3B against $606.4M for Insmed.

Which has the higher operating margin?

Viatris: -18.6%, against -206% for Insmed. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Viatris: 2.31%, against 0.00% for Insmed. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Viatris: $14.4B, against $546.8M for Insmed. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Insmed and Viatris?

None of the tracked superinvestors holds both in their latest 13F filing. 7 hold Insmed and 9 hold Viatris.

Cite this page

Funkfolio, “Insmed vs Viatris”, data as of 18 November 2026. https://funkfolio.com/compare/insm-vs-vtrs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.